These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8433280)

  • 21. Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: a guide for drug design.
    Kaplan AH
    AIDS Res Hum Retroviruses; 1996 Jul; 12(10):849-53. PubMed ID: 8798968
    [No Abstract]   [Full Text] [Related]  

  • 22. Polymorphisms in p1-p6/p6* of HIV type 1 can delay protease autoprocessing and increase drug susceptibility.
    Whitehurst N; Chappey C; Petropoulos C; Parkin N; Gamarnik A
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):779-84. PubMed ID: 14585208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
    Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of HIV by an anti-HIV protease synthetic peptide blocks an early step of viral replication.
    Venaud S; Yahi N; Fehrentz JL; Guettari N; Nisato D; Hirsch I; Chermann JC
    Res Virol; 1992; 143(5):311-9. PubMed ID: 1480823
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease.
    Serio D; Singh SP; Cartas MA; Weber IT; Harrison RW; Louis JM; Srinivasan A
    Protein Eng; 2000 Jun; 13(6):431-6. PubMed ID: 10877854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [HIV protease inhibitors (new possibilities in the treatment of HIV infection and AIDS)].
    Bálint GS
    Orv Hetil; 1998 Jun; 139(24):1471-4. PubMed ID: 9658865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An HIV-1 protease screening assay using a non-infectious proviral clone.
    Heldsinger AA; Antonucci T
    J Virol Methods; 1994 Oct; 49(3):247-55. PubMed ID: 7868643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptive inhibitors of the HIV-1 protease.
    Ohtaka H; Freire E
    Prog Biophys Mol Biol; 2005 Jun; 88(2):193-208. PubMed ID: 15572155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The development of anti-HIV-1 drugs.
    Lu XF; Chen ZW
    Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking of human immunodeficiency virus type-1 virion autolysis by autologous p2(gag) peptide.
    Misumi S; Morikawa Y; Tomonaga M; Ohkuma K; Takamune N; Shoji S
    J Biochem; 2004 Mar; 135(3):447-53. PubMed ID: 15113844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges.
    Voshavar C
    Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.
    Schubert U; Ott DE; Chertova EN; Welker R; Tessmer U; Princiotta MF; Bennink JR; Krausslich HG; Yewdell JW
    Proc Natl Acad Sci U S A; 2000 Nov; 97(24):13057-62. PubMed ID: 11087859
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.
    Ott DE; Coren LV; Chertova EN; Gagliardi TD; Nagashima K; Sowder RC; Poon DT; Gorelick RJ
    J Virol; 2003 May; 77(10):5547-56. PubMed ID: 12719547
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells.
    Goto T; Nakano T; Kohno T; Morimatsu S; Morita C; Hong W; Kiso Y; Nakai M; Sano K
    J Med Virol; 2001 Mar; 63(3):203-9. PubMed ID: 11170058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity.
    Martinez ZS; Castro E; Seong CS; Cerón MR; Echegoyen L; Llano M
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5731-41. PubMed ID: 27431232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent developments of peptidomimetic HIV-1 protease inhibitors.
    Qiu X; Liu ZP
    Curr Med Chem; 2011; 18(29):4513-37. PubMed ID: 21864279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
    Uchida H; Maeda Y; Mitsuya H
    Antiviral Res; 1997 Nov; 36(2):107-13. PubMed ID: 9443667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy.
    Servais J; Lambert C; Fontaine E; Plesséria JM; Robert I; Arendt V; Staub T; Schneider F; Hemmer R; Burtonboy G; Schmit JC
    J Clin Microbiol; 2001 Feb; 39(2):454-9. PubMed ID: 11158089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.